This episode features Dr. Aleppo, an endocrinologist, who has a commercial relationship with Insulet and was compensated for her participation in the podcast.

Dr. Grazia Aleppo returns to Beyond the Bolus to share her insights from ADA 2025 and beyond. In this engaging conversation, Dr. Aleppo discusses the evolution of automated insulin delivery (AID) systems, the RADIANT and SECURE-T2D clinical trials, and why Omnipod® 5 is changing the game for people with both type 1 and type 2 diabetes. From helping patients to overcome fears of hypoglycemia to simplifying care, Dr. Aleppo emphasizes the importance of challenging outdated assumptions about who benefits from AID and underscores the need for simple, more adaptable solutions for every patient.

This episode features Dr. DeSalvo, a pediatric endocrinologist, who has a commercial relationship with Insulet and was compensated for his participation in the podcast.

In this episode of Beyond the Bolus, Dr. Daniel DeSalvo shares his experience caring for teens with type 1 diabetes - and why this population deserves more credit than they often get. From navigating diabetes distress to celebrating wins in the classroom, on the field, and in the orchestra pit, Dr. DeSalvo highlights how Omnipod® 5 can help shift diabetes from the foreground to the background.

With practical tips for system optimization and heartfelt stories of transformation, this episode is a must-listen for anyone caring for teens with type 1 diabetes.

In this special ADA 2025 edition of Beyond the Bolus, hosts Nancy Hanna and Cindy Pickering sit down with Cari Berget, RN, CDCES from the Barbara Davis Center, to unpack the newly published paper, Practical considerations for using the Omnipod 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Drawing on years of real-world experience, Cari shares evidence-backed strategies to start patients on AID confidently, optimize settings, personalize targets, and simplify bolusing - even without perfect carb counting.

From pediatrics to older adult care, this episode is packed with actionable tips, memorable vignettes, and key takeaways to support success with Omnipod 5 across diverse patient populations.

In this heartfelt and insightful episode of Beyond the Bolus, hosts Nancy Hanna and Dena Gottesman sit down with Dr. Kathy Sumpter, a pediatric endocrinologist who brings a unique dual perspective as both a healthcare provider and someone living with type 1 diabetes. Diagnosed at age 20, Dr. Sumpter shares her personal journey and how it shaped her mission to support children and teens navigating diabetes.

Together, they explore the evolution of diabetes technology, the transformative impact of the Omnipod 5 system, and how it helps families manage diabetes more confidently, from toddlers to teens. Dr. Sumpter offers practical advice for clinicians, discusses the emotional realities of diabetes care, and emphasizes the importance of meeting families where they are.

Whether you're a healthcare provider, caregiver, or someone living with diabetes, this episode is packed with empathy, expertise, and inspiration.

In this special ADA 2025 edition of Beyond the Bolus, host Nancy sits down with Kellee Miller and Jennifer Boyd from Insulet’s Medical Affairs team to discuss groundbreaking data on the Omnipod 5 Automated Insulin Delivery System in people with type 2 diabetes. From real-world evidence across 23,000+ users to insights on insulin dosing, quality of life, and optimized settings, this episode dives deep into how Omnipod 5 is transforming diabetes care. Whether you're a prescriber, educator, or caring for someone living with diabetes, this conversation offers valuable takeaways on the future of AID technology.

How can AID systems like Omnipod 5 ease the mental burden on patients living with diabetes? To find out, Beyond the Bolus hosts Nancy Hanna and Dena Gottesman handed over hosting duties to our international colleague, Kate Neal, who was at ATTD in Amsterdam speaking with Dr. Eden Miller, a family practitioner, diabetologist, and co-founder of Diabetes Nation.

Dr. Miller shares her perspective (as both a healthcare provider and a person living with diabetes), explaining why she considers Omnipod 5 to be a “diabetes partner” – one that adapts and helps patients live more freely with less mental burden. They discuss how customizable glucose targets, setting adjustments, and the Custom Foods feature provide patients with a personalized and supportive experience.

Kate and Dr. Miller take a closer look at the SECURE-T2D study, which evaluated the use of Omnipod 5 in adults with type 2 diabetes. Dr. Miller outlines the key results and reflects on how the findings are already transforming her clinical practice.

You’ll also hear stories from Dr. Miller’s practice, such as a 78-year-old patient who was recently diagnosed with type 1 diabetes, and a 9-year-old who is learning independence - and managing type 1 diabetes – with the help of the Custom Foods feature. Dr. Miller

brings a practical, person-first approach to care, whether she’s breaking down barriers to technology, helping patients build confidence, or supporting them through the emotional side of diabetes.

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this episode, we dive into the SECURE T2D publication, with Dr. Chris Bajaj, an author and investigator in this groundbreaking study. Featuring a diverse population of participants with type 2 diabetes, the study revealed significant A1C reduction1, especially for those participants with baseline A1C above 9%. We also explore the simplified bolus strategies used to support patients, including those not carb counting at the start of the study. Tune in to learn how this research is shaping real-world diabetes care for people living with type 2 diabetes!

1. Pasquel FJ, et al. JAMA Network Open (2025). Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. In a subgroup analysis of 68 participants with baseline A1c ≥ 9% Mean HbA1c: ST vs. 13-week Omnipod 5: 10.1% vs. 8.1%; (95% CI: -2.3%, -1.9%)

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

In this Beyond the Bolus episode, Mark Heyman, PhD CDCES, shares his experience using the Omnipod 5 App for iPhone as part of the limited market release (LMR). Dr. Heyman discusses this system's new features and how these have benefited his mental well-being and reduced his diabetes distress. Dive in to hear how the Omnipod 5 App for iPhone could help enhance your patient's diabetes management!